Cardioprotective mechanisms of ACE inhibition. The angiotensin II-nitric oxide balance

Drugs

Volumn 54, Issue SUPPL.5, 1997, Pages 1-11

  Gibbons, Gary H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NITRIC OXIDE; VASOACTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HEART PROTECTION; HOMEOSTASIS; HUMAN; INTIMA; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; NONHUMAN; REVIEW;

ANIMALIA;

EID: 0030716751     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199700545-00003     Document Type: Review

References (74)

1. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. New Engl J Med 1994; 330: 1431-8
2. Gibbons GH. Mechanisms of vascular remodeling in hypertension: role of autocrine-paracrine vasoactive factors. Curr Opin Nephrol Hypertens 1995; 4: 189-96
3. Folkow B. Physiological aspects of primary hypertension. Physiol Rev 1982; 62: 347-504
4. Heagerty AM, Aalkjaer C, Bund SJ, et al. Small artery structure in hypertension. Dual processes of remodeling and growth. Hypertension 1993; 21: 391-7
5. Sivertsson R. The hemodynamic importance of structural vascular changes in essential hypertension. Acta Physiol Scand 1970; 343 Suppl.: 1-56
6. Cook TA, Yates PO. A histometric study of cerebral and renal arteries in normotensives and chronic hypertensives. J Pathol 1972; 108: 129-35
7. Fazekas F, Kleinart R, Offenbacher H, et al. The morphologic correlate of incidental punctate white matter hyperintensities on MR images. Am J Neuroradiol 1991; 12: 915-21
8. Ito A, Egashira K, Kadokami T, et al. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation 1995; 92 (9): 2636-44
9. Liao Y, Cooper RS, McGee DL, et al. The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA 1995; 273 (20): 1592-7
10. Hampton JA, Bernardo DA, Khan NA, et al. Morphometric evaluation of the renal arterial system of Dahl salt-sensitive and salt-resistant rats on a high salt diet. II. Interlobular arteries and intralobular arterioles. Lab Invest 1989; 60 (6): 839-46
11. Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334 (1): 13-8
12. Boutouyrie P, Laurent S, Girerd X, et al. Common carotid artery stiffness and patterns of left ventricular hypertrophy in hypertensive patients. Hypertension 1995; 25 (4 Pt 1): 651-9
13. Mintz GS, Popma JJ, Pichard AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation, 1996; 94 (1): 35-43
14. Lim TT, Liang DH, Botas J, et al. Role of compensatory enlargement and shrinkage in transplant coronary artery disease: serial intravascular ultrasound study. Circulation 1997; 95: 855-9
15. Glagov S, Weisenberg E, Zarins CK, et al. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-5
16. Hermiller JB, Tenaglia AN, Kisslo KB, et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol 1993; 71: 665-8
17. Chobanian AV, Alexander RW. Exacerbation of atherosclerosis by hypertension. Potential mechanisms and clinical implications. Arch Intern Med 1996; 156 (17): 1952-6
18. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493-8
19. Thybo NK, Korsgaard N, Eriksen S, et al. Dose-dependent effects of perindopril on blood pressure and small artery structure. Hypertension 1994; 23: 659-66
20. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 1): 474-81
21. Itoh H, Mukoyama M, Pratt RE, et al. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-74
22. Sudhir K, Wilson E, Chatterjee K, et al. Mechanical strain and collagen potentiate mitogenic activity of angiotensin II in rat vascular smooth muscle cells. J Clin Invest 1993; 92: 3003-7
23. Griendling KK, Ushio-Fukai M, Lassegue B, et al. Angiotensin II signaling in vascular smooth muscle: new concepts. Hypertension 1997; 29 (Pt 2): 366-73
24. Isner JM, Kearney M, Bortman S, et al. Apoptosis in human atherosclerosis and restenosis. Circulation 1995; 91 (11): 2703-11
25. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Colocalization with interleukin-I beta-converting enzyme. Am J Pathol 1995; 147 (2): 251-66
26. Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 1995; 95 (5): 2266-74
27. Pollman MJ, Yamada T, Horiuhi M, et al. Vasoactive substances regulate vascular smooth muscle cell apoptosis: countervailing influences of nitric oxide and angiotensin II. Circ Res 1996; 79: 748-56
28. de Blois D, Tea BS, Dam TV, et al. Smooth muscle apoptosis during vascular regression in spontaneously hypertensive rats. Hypertension 1997; 29: 340-9
29. Levy BI, Benessiano J, Henrion D, et al. Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98 (2): 418-25
30. van Leeuwen RTJ, Kol A, Andreotti F, et al. Angiotensin II increases plasminogen activator inhibitor type I and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 1994; 90: 362-8
31. deBlois D, Lambardi DM, Su EJ, et al. Angiotensin II induction of osteopontin expression and DNA replication in rat arteries. Hypertension 1996; 28: 1055-63
32. Dubey RK, Jackson EK, Luscher TF. Nitric oxide inhibits angiotensin II-induced migration of rat aortic smooth muscle cell. Role of cyclic-nucleotides and angiotensin 1 receptors. J Clin Invest 1995; 96 (1): 141-9
33. Majesky MW, Daemen MJAP, Schwartz SM. Alpha 1-adrenergic stimulation of platelet-derived grow th factor A-chain gene expression in rat aorta. J Biol Chem 1990; 265: 1082-8
34. Bevan RD. Trophic effects of peripheral adrenergic nerves on vascular structure. Hypertension 1984; 6 Suppl. III: III-19-III-26
35. Li JS, Lariviere R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24: 183-8
36. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7
37. Morishita R, Gibbons GH, Pratt RE, et al. Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest 1994; 94: 824-9
38. von der Leyen H, Gibbons GH, Morishita R, et al. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 1995; 92: 1137-41
39. Rajagopalan S, Meng SXP, Ramasamy S, et al. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-9
40. Ohno M, Gibbons GH, Dzau VJ, et al. Shear stress elevates endothelial cGMP. Role of a potassium channel and G protein coupling. Circulation 1993; 88 (1): 193-7
41. Tronc F, Wassef M, Esposito B, et al. Role of NO in flow-induced remodeling of the rabbit common carotid artery. Arterioscler Thromb Vasc Biol 1996; 16 (10): 1256-62
42. Moroi M, Gold HK, Yasuda T, et al. Mice mutant in endothelial nitric oxide synthase: vessel growth and response to injury [abstract]. Circulation 1996; 94: I-154
43. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996; 94 (3): 258-65
44. Iwatsubo H, Nagano M, Sakai T, et al. Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29 (Pt 2): 286-90
45. Panza JA, Garcia CE, Kilcoyne CM, et al. Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995; 91 (6): 1732-8
46. Taddei S, Virdis A, Mattei P, et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 Suppl. 12: S193-5
47. Stamler JS. Redox signaling: nitrosylation and related target interactions of nitricoxide. Cell 1994; 78 (6): 931-6
48. Nakazono K, Watanabe N, Matsuno K, et al. Does superoxide underlie the pathosenesis of hypertension? Proc Natl Acad Sci USA 1991; 88 (22): 10045-8
49. Tschudi MR, Mesaros S, Luscher TF, et al. Direct in situ measurement of nitric oxide in mesenteric resistance arteries. Increased decomposition by superoxide in hypertension. Hypertension 1996; 27 (1): 32-5
50. Rajagopalan S, Kurz S, Munzel T, et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 1996; 97 (8): 1916-23
51. Ushio-Fukai M, Zafari AM, Fukui T, et al. p22phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 1996; 271: 23317-21
52. Tsai JC, Jain M, Hsieh CM, et al. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J Biol Chem 1996; 271 (7): 3667-70
53. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91 (9): 2488-96
54. Lüscher TF, Vanhoutte PM, Raij L. Antihypertensive treatment normalizes decreased endothelium dependent relaxations in rats with salt-induced hypertension. Hypertension 1987; 9 Suppl. III: III-193-III-197
55. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol 1996; 28 (5): 851-8
56. Zisman LS, Abraham WT, Meixell GE, et al. Angiotensin II formation in the intact human heart. Predominance of the angiotensin-converting enzyme pathway. J Clin Invest 1995; 96 (3): 1490-8
57. Hokimoto S, Yasue H, Fujimoto K, et al. Expression of angiotensin-converting enzyme in remaining viable myocytes of human ventricles after myocardial infarction. Circulation 1996; 94 (7): 1513-8
58. Takemoto M, Egashira K, Usui M, et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest 1997; 99 (2): 278-87
59. Diet F, Pratt RE, Berry GJ, et al. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94 (11): 2756-67
60. Kitazono T, Padgett RC, Armstrong ML, et al. Evidence that ansiotensin II is present in human monocytes. Circulation 1995; 91 (4): 1129-34
61. Xiong W, Chao J, Chao L. Muscle delivery of human kallikrein gene reduces blood pressure in hypertensive rats. Hypertension 1995; 25 (4 Pt 2): 715-9
62. Alfie ME, Yang X, Hess F, et al. Salt-sensitive hypertension in bradykinin B-2 receptor knockout mice. Biochem Biophys Res Commun 1996; 224: 625-30
63. Zhang X, Xie YW, Nasjletti A, et al. ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption. Circulation 1997; 95 (1): 176-82
64. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation 1997; 95: 1115-8
65. Harrap SB, Van der Merwe WM, Griffin SA, et al. Brief angiotensin converting enzyme inhibitor treatment in young spontaneously hypertensive rats reduces blood pressure long-term. Hypertension 1990; 16: 603-14
66. Dahlof B, Hansson L. The influence of antihypertensive therapy on the structural arteriolar changes in essential hypertension: different effects of enalapril and hydrochlorothiazide. J Intern Med 1993; 234: 271-9
67. Thybo NK, Stephens N, Cooper A, et al. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 1995; 25 (4 Pt 1): 474-81
68. Skov K, Fenger-Gron J, Mulvany MJ. Effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist, and an endothelin receptor antagonist on renal afferent arteriolar structure. Hypertension 1996; 28 (3): 464-71
69. Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993; 329 (20): 1456-62
70. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-depcndent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156 (3): 286-9
71. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996; 334 (15): 939-45
72. GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-63
73. Rutherford JD, Pfeffer MA, Moye LA, et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 1994; 90 (4): 1731-8
74. Pepine CJ. Ongoing clinical trials of angiotensin-converting enzyme inhibitors for treatment of coronary artery disease in patients with preserved left ventricular function. J Am Coll Cardiol 1996; 27 (5): 1048-52